We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
51
CALL
Ionis Pharmaceuticals
IONS
$8.93B
$7.96M 0.3%
2,171
-1,429
-40% -$44.7K
CLVS
52
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$7.54M 0.28%
2,091
+1,988
+1,930% +$42.7K
ABBV icon
53
PUT
AbbVie
ABBV
$465B
$7.43M 0.28%
1,178
-1,169
-50% -$75.7K
HZNP
54
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.41M 0.28%
4,088
+1,883
+85% +$36.8K
ACHN
55
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$7.32M 0.27%
9,039
+5,212
+136% +$44.3K
CEMP
56
CALL
DELISTED
Cempra, Inc.
CEMP
$7.31M 0.27%
3,019
+1,482
+96% +$31.9K
THC icon
57
CALL
Tenet Healthcare
THC
$22.2B
$7.2M 0.27%
3,179
+3,098
+3,825% +$80.6K
FOLD
58
CALL
DELISTED
Amicus Therapeutics
FOLD
$7.13M 0.27%
9,632
+1,640
+21% +$11.1K
DXCM icon
59
CALL
DexCom
DXCM
$29B
$7.07M 0.26%
3,224
-1,496
-32% -$33.3K
ISEE
60
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7M 0.26%
1,517
+1,156
+320% +$65.2K
EXEL icon
61
PUT
Exelixis
EXEL
$13.9B
$6.9M 0.26%
+5,392
New +$58.3K
KITE
62
PUT
DELISTED
Kite Pharma, Inc.
KITE
$6.58M 0.25%
+1,177
New +$65.6K
SIOX
63
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.55M 0.25%
+585
New +$70.2K
IOVA icon
64
PUT
Iovance Biotherapeutics
IOVA
$2.04B
$6.5M 0.24%
7,901
+375
+5% +$3.17K
NBIX icon
65
CALL
Neurocrine Biosciences
NBIX
$18.2B
$6.15M 0.23%
1,214
+401
+49% +$20K
GILD icon
66
PUT
Gilead Sciences
GILD
$165B
$6.1M 0.23%
+771
New +$62.6K
KITE
67
CALL
DELISTED
Kite Pharma, Inc.
KITE
$6.04M 0.23%
1,082
+231
+27% +$12.9K
SHPG
68
DELISTED
Shire pic
SHPG
$6.04M 0.23%
31,172
+1,622
+5% +$316K
HALO icon
69
CALL
Halozyme
HALO
$9.88B
$5.92M 0.22%
4,901
+2,800
+133% +$28.6K
ALNY icon
70
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
$5.89M 0.22%
869
+263
+43% +$18.6K
PTCT icon
71
CALL
PTC Therapeutics
PTCT
$6.18B
$5.59M 0.21%
3,989
+2,249
+129% +$18.3K
TENX icon
72
Tenax Therapeutics
TENX
$393M
$5.55M 0.21%
75
-6
-7% -$473K
DVAX
73
DELISTED
Dynavax Technologies
DVAX
$5.47M 0.21%
521,875
+231,370
+80% +$3.33M
SAGE
74
CALL
DELISTED
Sage Therapeutics
SAGE
$5.37M 0.2%
1,165
-2,844
-71% -$116K
HUM icon
75
CALL
Humana
HUM
$43.9B
$4.92M 0.18%
+278
New +$48.2K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.